Experimental ASO treatment for TUBB4A-related leukodystrophy
Part of Genetic & congenital clinical trials.
This trial tests a single patient's response to an experimental genetic treatment (called an ASO) for a rare brain disease caused by changes in the TUBB4A gene. The goal is to see if the treatment can improve symptoms related to the condition H-ABC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have a confirmed genetic change (mutation) in the TUBB4A gene.
- The diagnosis should match a brain condition called H-ABC (Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum).
- You must be able to travel to the study site and follow up regularly.
- You must be willing to have a lumbar puncture (a needle in the lower back to collect fluid).
- You cannot have taken any other experimental drug within the last few weeks (or longer, depending on the drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new genetic medicine designed for people with A-T who have a specific ATM gene change. It aims to see if the treatment is safe and if it can improve symptoms.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
This trial offers a custom-made treatment for people with ALS caused by a TARDBP gene mutation. It uses a personalized medicine approach to target the specific genetic cause of the disease.
This study tests an experimental medication called TB006 for adults with autism. It aims to see if it can help reduce symptoms. Participants must be 18–35, have moderate-to-severe autism, and have a caregiver who can join them.
This study tests whether a new medicine called AOC 1044 (delpacibart zotadirsen) can help boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The medicine works by helping the body skip a damaged part of the gene to make a functional protein.
Hear when a new Genetic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.